These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1972133)

  • 21. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both.
    Langenmayer I; Weaver C; Buckner CD; Lilleby K; Appelbaum FR; Longin K; Rowley S; Storb R; Singer J; Bensinger WI
    Bone Marrow Transplant; 1995 Feb; 15(2):241-6. PubMed ID: 7773213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
    McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
    Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous blood stem cell transplantation as intensive consolidation therapy in hematological malignancies.
    Fioritoni G; Iacone A; D'Antonio D; Dragani A; Quaglietta AM; Accorsi P; Angelini A; Spadano A; Natale D; Berardi A
    Haematologica; 1990; 75 Suppl 1():60-4. PubMed ID: 1972130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation.
    Tarella C; Gavarotti P; Caracciolo D; Locatelli F; Falda M; Paolino F; Lovisone E; Sormano E; Tassi V; Urgesi A
    Haematologica; 1990; 75 Suppl 1():90-4. PubMed ID: 1972137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of moderate-grade and high-grade malignant lymphoma with autologous hematopoietic stem cell transplantation].
    Wang AL; He ZD; Luo Y; Xiao LX; Liu XY; Zhu YH
    Ai Zheng; 2003 Dec; 22(12):1317-20. PubMed ID: 14693059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Collection of blood stem cells and therapeutic applications].
    Reiffers J; Boiron JM; Marit G; Bouzgarrou R; Bernard P; David B; Foures C; Broustet A; Vezon G
    Ann Med Interne (Paris); 1988; 139 Suppl 1():3-6. PubMed ID: 2907850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
    Chou T; Ishiguro T; Imajo K; Kawano F; Gondo H; Kasai M; Masuda M; Koike M; Shimazaki C; Hara M; Shinagawa K; Ogawa M; Takaku F; Harada M
    Rinsho Ketsueki; 1999 Oct; 40(10):1058-67. PubMed ID: 10565222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
    Seropian S; Bahceci E; Cooper DL
    Bone Marrow Transplant; 2003 Oct; 32(8):763-9. PubMed ID: 14520419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.